兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06622 兆科眼科-B

已收盘 08-20 15:48:35

2.530

+0.010

+0.40%

最高2.595	最低2.500	成交量13.90万
今开2.535	昨收2.520	日振幅3.77%
总市值13.89亿	流通市值13.89亿	总股本5.49亿
成交额35.14万	换手率0.03%	流通股本5.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06622","market":"HK","secType":"STK","nameCN":"兆科眼科-B","latestPrice":2.53,"timestamp":1787212115598,"preClose":2.52,"halted":0,"volume":139000,"delay":0,"changeRate":0.003968253968253884,"floatShares":549000000,"shares":549000000,"eps":-0.382096,"marketStatus":"已收盘","change":0.01,"latestTime":"08-20 15:48:35","open":2.535,"high":2.595,"low":2.5,"amount":351375,"amplitude":0.037698,"askPrice":2.53,"askSize":500,"bidPrice":2.52,"bidSize":20000,"shortable":0,"etf":0,"ttmEps":-0.4252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"listingDate":1619625600000,"exchange":"SEHK","adjPreClose":2.52,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":1.074189,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06622","defaultTab":"news","newsList":[{"id":"1144431392","title":"兆科眼科-B（06622）公告8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1144431392","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144431392?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:56","pubTimestamp":1786956968,"startTime":"0","endTime":"0","summary":"兆科眼科-B（06622）8月17日发布董事会会议通告，公司董事会将于2026年8月28日（星期五）召开会议，拟审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审核中期业绩及其刊发事宜。\n本次会议同时将处理与中期业绩相关的其他事项。\n公告显示，截至公告日期，兆科眼科-B董事会成员包括：执行董事李小羿博士、戴向荣先生；非执行董事李烨妮女士、张甜甜女士；独立非执行董事黄显荣先生、卢毓琳教授及刘怀镜先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119634","title":"港股异动 | 李氏大药厂(00950)涨超7% ZK2401于中国提交新药临床试验申请已获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659119634?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:36","pubTimestamp":1786692986,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，李氏大药厂涨超7%，截至发稿，涨7.27%，报1.18港元，成交额201.32万港元。消息面上，近期，李氏大药厂发布公告，本集团就ZK2401于中国的新药临床试验申请已获得中国国家药品监督管理局药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物项目，由李氏大药厂拥有该分子的完整全球知识产权。作为李氏大药厂ADC平台的首个项目，ZK2401标志着本集团推进该平台发展的一个重要起点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BMED","MDTX","KCAI","IBBJ","BK4588","BK4585","06622","IBBQ","VXUS","PSYK","BK1583","00950","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978682","title":"兆科眼科-B(06622.HK)与澎湃生物医药就盐酸依匹斯汀滴眼液订立独家分销及推广协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978682?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:55","pubTimestamp":1786524923,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","06622","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199644797","title":"兆科眼科-B签订盐酸依匹斯汀滴眼液中国内地商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1199644797","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199644797?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:55","pubTimestamp":1786524909,"startTime":"0","endTime":"0","summary":"兆科眼科-B（ZHAOKE OPHTH-B）近日宣布，已签署一项重要协议。该协议旨在中国内地（不含香港、澳门及台湾地区）推进盐酸依匹斯汀滴眼液的商业化进程。此举标志着这家眼科制药企业，在深耕中国市场的道路上又迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","06622","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667506","title":"李氏大药厂(00950.HK)转仓市值总计4607.25万港元 占比7.24% 从南洋商业银行转出4243.83万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667506?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:27","pubTimestamp":1786062441,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1231","06622","BK1560","BK1191","BK1587","00950","BK1583","BK1574","09668"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155945195","title":"兆科眼科-B公布2026年7月股份变动月报，股本继续维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1155945195","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155945195?lang=zh_cn&edition=full","pubTime":"2026-08-03 13:11","pubTimestamp":1785733909,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年8月3日发布截至2026年7月31日止月份的证券变动月报。报告显示，公司法定/注册股本维持在1,600,000,000,000股，面值0.00000025美元，总额400,000美元，与上月保持一致。公司已发行普通股股数截至2026年7月31日为548,749,012股，未有新增发行或注销动作，也无库藏股数量变化。公司确认其于本月内的证券发行及库存股份出售或转让均符合香港联交所《上市规则》和有关法律及监管规定。公告由公司董事李小羿签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655059788","title":"李氏大药厂(00950.HK)：专有ADC项目ZK2401于中国提交新药临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655059788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655059788?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:13","pubTimestamp":1785420782,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","06622","BK1191","BK1574","BK1583","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655846808","title":"一边亏着两个亿，一边押注全球阿托品：兆科眼科的近视神药豪赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2655846808","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655846808?lang=zh_cn&edition=full","pubTime":"2026-07-30 09:10","pubTimestamp":1785373839,"startTime":"0","endTime":"0","summary":"悬崖边上，落子全球棋局。兆科眼科（6622.HK）近日发布自愿性公告称，公司已于2026年6月22日订立最终协议，收购硫酸阿托品滴眼液NVK002的全球权利。据协议条款，兆科眼科将取得与NVK002相关的全部知识产权、商标、监管档案、临床数据、制造能力及其他相关资产的全球拥有权，全面掌控该产品在全球的开发、制造及商业化工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303825997988.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303825997988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1191","BK1587","06622","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152918833","title":"兆科眼科-B（06622）老花眼创新药YUVEZZI™获澳门药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1152918833","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152918833?lang=zh_cn&edition=full","pubTime":"2026-07-20 12:06","pubTimestamp":1784520369,"startTime":"0","endTime":"0","summary":"兆科眼科-B7月20日公告称，其创新药YUVEZZI已于2026年7月13日获澳门特别行政区政府药物监督管理局批准，用于治疗老花眼。Tenpoint已于2026年1月获得美国食品药品监督管理局批准，将该药用于治疗通常在45岁左右发病的老花眼。同年6月，海南省药品监督管理局亦批准该药作为博鳌超级医院的临床急需进口药品使用。\\n\\n兆科眼科-B提醒股东及潜在投资者，依据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证最终能成功开发或商业化该药品。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652028501","title":"李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652028501","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652028501?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:36","pubTimestamp":1784295413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. 订立独家许可协议。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06622","BK1583","00950","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","01672","02137","06606","02269","BK1574","06996","BK1161","09966","IBBQ","06618","09995","09606","00241","03759","159992","01801","MEDX","09688","06978","03347","02359","02268"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651212817","title":"港股公告掘金 | 佑驾创新与滴滴送货建立长期战略合作关系 拟共同推动城市末端无人配送商业化、规模化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651212817","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651212817?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:47","pubTimestamp":1783990072,"startTime":"0","endTime":"0","summary":"重大事项：兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利脑动极光-B(06681)荣获第三届雄安垂直大模型应用大赛亚军及最新临床科研成果在国际权威期刊发表胜宏科技(02476)澄清网络不实负面传闻 AI PCB 订单持续增长佑驾创新(02431)与滴滴送货建立长期战略合作关系 拟共同推动城市末端无人配送商业化、规模化落地恒瑞医药(01276)：HRS-705","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","VXUS","01336","LU1008478684.HKD","06681","LU0650527681.SGD","BK4588","LU0067412154.USD","BK1184","IE00B3M56506.USD","BK1240","BK4585","DIDIY","LU0359202008.SGD","LU1807302812.USD","LU0738912210.USD","LU2088748293.HKD","LU0791590937.USD","SG9999014674.SGD","01109","LU0173614495.USD","LU0880133367.SGD","LU0359201612.USD","LU0211977185.USD","LU0348827113.USD","LU0072913022.USD","HK0000320223.HKD","LU0370786039.SGD","BK1555","LU0287142896.SGD","LU0516422952.EUR","BK1189","LU0594300179.USD","02431","HK0000320264.USD","BK1191","LU2088748020.USD","HK0000306685.HKD","BK1570","BK1589","LU0516422366.SGD","LU0516423174.USD","LU0791591158.USD","KCAI","BK1144","HK0000306701.USD","LU0516423091.SGD","LU1242518857.USD","SG9999009997.SGD","LU0048580855.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137128045","title":"兆科眼科-B敲定最终协议 收购Nvk002全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1137128045","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137128045?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:51","pubTimestamp":1783932713,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司已就收购Nvk002的全球权益签署了最终协议。此举标志着该公司在拓展其眼科产品管线方面迈出了关键一步，旨在通过引入新的治疗资产来增强其长期增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06622","BK1191","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651929681","title":"兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2651929681","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651929681?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:49","pubTimestamp":1783932559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B 发布公告，于2026年6月22日，公司已收购NVK002的全球权利。NVK002此一产品旨在减慢儿童近视加深。根据协议条款，公司将取得与NVK002相关的所有知识产权、商标、监管存档、临床数据、制造能力及其他相关资产的全球拥有权。本次收购让公司可全面控制该产品在全球的开发、制造及商业化工作。作为交易的一部分，公司已向NVK002的卖方授出一项永久性的免专利权费专属许可，该项权利已出让予Nevakar Pharmaceuticals,Inc.，以于美国开发及商业化NVK002。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1191","BK1574","06622","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182810656","title":"兆科眼科授予Nevakar制药公司美国Nvk002永久免版税独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1182810656","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182810656?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:48","pubTimestamp":1783932504,"startTime":"0","endTime":"0","summary":"兆科眼科已授予Nevakar制药公司一项关于Nvk002的永久、免版税、在美国的独家许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06622","BK1587","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160013342","title":"兆科眼科-B：7月9日回购8,500股，耗资约2.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160013342","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160013342?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:32","pubTimestamp":1783589572,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年7月9日公告，于香港联合交易所场内回购公司股份8,500股，占已发行股本约0.0015%，回购价格介乎每股港币2.58元至2.62元，合计支付约2.21万港元。根据翌日披露报表，本次回购后公司已发行股本仍为548,749,012股，暂未产生库藏股变动。公司于2026年5月15日通过购回授权，可购回最多54,874,901股。公司确认本次回购已获得董事会正式授权，遵守了香港联合交易所证券上市规则及相关法律规定。公告由董事李小羿签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B：7月9日回购8,500股，耗资约2.21万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650492886","title":"兆科眼科-B(06622)7月9日斥资2.21万港元回购8500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650492886","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650492886?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:32","pubTimestamp":1783589552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)发布公告，于2026年7月9日斥资2.21万港元回购8500股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06622","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116537093","title":"兆科眼科-B - Yuvezzitm 获准在博鳌超级医院作为临床急需进口药物使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1116537093","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116537093?lang=zh_cn&edition=full","pubTime":"2026-07-07 12:06","pubTimestamp":1783397211,"startTime":"0","endTime":"0","summary":"兆科眼科-B 宣布，其药物 Yuvezzitm 已获准在海南博鳌超级医院作为临床急需进口药物投入临床使用。此举标志着该产品在满足特定临床需求方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06622","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177330865","title":"兆科眼科-B7月6日回购11,000股，耗资约2.91万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177330865","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177330865?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:04","pubTimestamp":1783382665,"startTime":"0","endTime":"0","summary":"兆科眼科-B于2026年7月6日发布翌日披露公告，披露当日通过香港联交所场内回购普通股11,000股，每股回购价介乎港币2.638元至2.65元，合计付出价格29,104.90港元。该回购股份数量约占公司现有已发行股本的0.002%。根据2026年5月15日通过的股份回购授权，兆科眼科-B可回购最多54,874,901股。公司同时确认，回购过程符合香港联交所证券上市规则及相关法律法规的要求。上述公告由公司董事李小羿签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B7月6日回购11,000股，耗资约2.91万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867738","title":"兆科眼科-B(06622.HK)7月6日斥资2.91万港元回购1.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649867738?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:02","pubTimestamp":1783382571,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","06622","BK1583","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":-0.0308},{"period":"3month","weight":-0.0418},{"period":"6month","weight":-0.2632},{"period":"1year","weight":-0.3942},{"period":"ytd","weight":-0.1486}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"兆科眼科有限公司是一家主要从事眼科药物及产品的开发、生产及营销的投资控股公司。该公司的主要产品包括用于治疗近视的NVK002（阿托品）、用于治疗干眼症的环孢素A眼凝胶以及用于治疗wAMD的TAB014（贝伐单抗）。该公司产品主要用于干眼症（DED）、近视、老花眼、湿性老年黄斑部病变（wAMD）和糖尿病黄斑水肿（DME）、青光眼及角膜上皮细胞功能障碍（CED）等影响眼前节及眼后节的眼科疾病的治疗。该公司在中国国内及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.147188},{"month":2,"riseRate":0.2,"avgChangeRate":-0.134185},{"month":3,"riseRate":0.2,"avgChangeRate":-0.040318},{"month":4,"riseRate":0.2,"avgChangeRate":0.019445},{"month":5,"riseRate":0.333333,"avgChangeRate":0.015956},{"month":6,"riseRate":0.166667,"avgChangeRate":0.033584},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.047805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.012},{"month":9,"riseRate":0.6,"avgChangeRate":0.007418},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082811},{"month":11,"riseRate":0.4,"avgChangeRate":0.029799},{"month":12,"riseRate":0.2,"avgChangeRate":-0.018114}],"exchange":"SEHK","name":"兆科眼科-B","nameEN":"ZHAOKE OPHTH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兆科眼科-B,06622,兆科眼科-B股票,兆科眼科-B股票老虎,兆科眼科-B股票老虎国际,兆科眼科-B行情,兆科眼科-B股票行情,兆科眼科-B股价,兆科眼科-B股市,兆科眼科-B股票价格,兆科眼科-B股票交易,兆科眼科-B股票购买,兆科眼科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}